| scholarly article | Q13442814 |
| P2093 | author name string | Juanita Crook | |
| Ana Fernandez-Ots | |||
| P2860 | cites work | Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial | Q30440940 |
| Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy | Q33371450 | ||
| Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer. | Q33403022 | ||
| Increasing treatment accuracy for cervical cancer patients using correlations between bladder-filling change and cervix-uterus displacements: proof of principle. | Q33812383 | ||
| Toward an individualized target motion management for IMRT of cervical cancer based on model-predicted cervix-uterus shape and position | Q33891816 | ||
| Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. | Q34009168 | ||
| Individualized nonadaptive and online-adaptive intensity-modulated radiotherapy treatment strategies for cervical cancer patients based on pretreatment acquired variable bladder filling computed tomography scans | Q34136437 | ||
| Radiation-induced second cancers: the impact of 3D-CRT and IMRT | Q34190538 | ||
| Dosimetric comparison of intensity-modulated, conformal, and four-field pelvic radiotherapy boost plans for gynecologic cancer: a retrospective planning study. | Q34646432 | ||
| Clinical application of intensity-modulated radiotherapy for locally advanced cervical cancer | Q34739888 | ||
| The effect of uterine motion and uterine margins on target and normal tissue doses in intensity modulated radiation therapy of cervical cancer | Q35196895 | ||
| Intensity-modulated radiation therapy, protons, and the risk of second cancers | Q36450877 | ||
| Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer | Q37013997 | ||
| Genetic markers for prediction of normal tissue toxicity after radiotherapy | Q37099948 | ||
| Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer | Q37753408 | ||
| Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies | Q38017760 | ||
| Cost-effectiveness of intensity-modulated radiotherapy in prostate cancer. | Q38019254 | ||
| Extended-field intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy for postoperative cervical cancer with common iliac or para-aortic lymph node metastases: a retrospective review in a single institution | Q38031381 | ||
| Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer | Q43251180 | ||
| Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin | Q43592469 | ||
| Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes | Q43796441 | ||
| Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer | Q44296363 | ||
| Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. | Q44780583 | ||
| Time course and incidence of late complications in patients treated with radiation therapy for FIGO Stage IB carcinoma of the uterine cervix | Q45026616 | ||
| Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer | Q48883038 | ||
| Incorporation of SPECT bone marrow imaging into intensity modulated whole-pelvic radiation therapy treatment planning for gynecologic malignancies. | Q50760896 | ||
| Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group stud | Q53346033 | ||
| Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer. | Q53497718 | ||
| The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy | Q57611584 | ||
| Pelvic Radiotherapy for Cancer of the Cervix: Is What You Plan Actually What You Deliver? | Q57617776 | ||
| Clinical Outcomes of Intensity-Modulated Pelvic Radiation Therapy for Carcinoma of the Cervix | Q62071379 | ||
| Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy | Q62071427 | ||
| Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies | Q73308604 | ||
| Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix | Q73675166 | ||
| Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation | Q74410489 | ||
| Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer | Q77321076 | ||
| Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies | Q77947552 | ||
| Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer | Q80055847 | ||
| Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy | Q80063601 | ||
| Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study | Q80336510 | ||
| An assessment of interfractional uterine and cervical motion: implications for radiotherapy target volume definition in gynaecological cancer | Q81420255 | ||
| Conventional, conformal, and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: The impact of tumor regression | Q81888873 | ||
| Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix | Q83737796 | ||
| Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT | Q84227409 | ||
| Extended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of arm II of Radiation Therapy Oncology Group (RTOG) 0116 | Q84889018 | ||
| Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer | Q85472143 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adaptive radiation therapy | Q180507 |
| P304 | page(s) | 363-70 | |
| P577 | publication date | 2013-10-03 | |
| P1433 | published in | Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology | Q26853947 |
| P1476 | title | The role of intensity modulated radiotherapy in gynecological radiotherapy: Present and future | |
| P478 | volume | 18 |
| Q36472605 | A novel dynamic field-matching technique for treatment of patients with para-aortic node-positive cervical cancer: Clinical experience |
| Q92861954 | High precision radiotherapy including intensity-modulated radiation therapy and pulsed-dose-rate brachytherapy for cervical cancer: a retrospective monoinstitutional study |
| Q90385053 | Lymph flow guided irradiation of regional lymph nodes in patients with cervical cancer: Preliminary analysis of scintigraphic data |
| Q90385036 | New developments and controversies in cervical cancer |
| Q41294321 | Outcomes with image-based interstitial brachytherapy for vaginal cancer |
| Q38225041 | Recent advances in radiation oncology: intensity-modulated radiotherapy, a clinical perspective |
| Q31019901 | Safety of adjuvant intensity-modulated postoperative radiation therapy in endometrial cancer: Clinical data and dosimetric parameters according to the International Commission on Radiation Units (ICRU) 83 report |
| Q37211731 | Should we customize PTV expansions for BMI? Daily cone beam computerized tomography to assess organ motion in postoperative endometrial and cervical cancer patients |
| Q36918472 | Survey on gynecological cancer treatment by Piedmont, Liguria, and Valle d'Aosta group of AIRO (Italian Association of Radiation Oncology) |
| Q90385077 | The role of para-aortic nodal irradiation in cervical cancer |
| Q36235565 | Validation of Fully Automated VMAT Plan Generation for Library-Based Plan-of-the-Day Cervical Cancer Radiotherapy. |
Search more.